Media releases Keyword Search Clear 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 23 December 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer Avastin represents first major treatment advance for women with ovarian cancer in 15 years. Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with ... more Published on: 16 December 2011 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult ... more Published on: 15 December 2011 Changes to the Roche Corporate Executive Committee Roche today announced that Sophie Kornowski-Bonnet, currently General Manager of Roche Pharma in France, has been appointed Head of Roche Partnering. Sophie Kornowski-Bonnet will assume her new role ... more Published on: 8 December 2011 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, ... more Published on: 7 December 2011 Roche establishes external Academic Translational Centre in Zurich Roche, together with ETH Zurich (Swiss Federal Institute of Technology, Zurich), the University of Zurich (UZH) and the University Hospital Zurich (USZ) announced today the formation of an external ... more Published on: 7 December 2011 Roche establishes external Academic Translational Centre in Zurich more Published on: 2 December 2011 Roche acquires Verum Diagnostica GmbH to strengthen portfolio in coagulation diagnostics Roche announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in ... more Published on: 1 December 2011 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for ... more Published on: 30 November 2011 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer ... more Published on: 29 November 2011 Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA) Collaboration offers new hope for a potential treatment for the leading genetic cause of death in infants and toddlers more Published on: 29 November 2011 Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA) more Published on: 28 November 2011 Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research Roche NimbleGen, Inc. and BGI, the world’s largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen ... more Published on: 18 November 2011 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of ... more Published on: 9 November 2011 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell ... more Published on: 8 November 2011 Roche announces commercial availability of the new Elecsys PTH (1–84) assay Fully automated assay provides accurate assessment of parathyroid function in patients with chronic kidney disease in routine clinical practice. Roche announces the market availability of the Elecsys ... more Published on: 3 November 2011 New study correlates sFlt-1/PIGF with disease severity in PE/HELLP Patients with a high sFlt-1/PIGF ratio show significantly increased risk for imminent delivery A new study now published in the American Journal of Obstetrics and Gynecology1 shows the ratio of angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF). ... more Published on: 3 November 2011 NT-proBNP–guided therapy reduces cardiovascular event rates and improved quality of life in heart failure patients Positive study results promote a new paradigm in the management of heart failure. In the recently published PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP ... more Published on: 20 October 2011 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple ... more Published on: 18 October 2011 Roche reports positive study of Herceptin given by subcutaneous injection Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a ... more Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 ... more Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals more Published on: 13 October 2011 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 ... more Published on: 11 October 2011 Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing Roche and Arizona Technology Enterprises announced today an agreement to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. ... more Published on: 10 October 2011 Study shows that Roche's investigational drug for Alzheimer's disease removes amyloid plaques from the brain Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer’s disease. The study ... more Published on: 10 October 2011 Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing. To enable researchers to ... more Published on: 4 October 2011 Roche Redefines Global Coagulation Diagnostics The market leader of in vitro diagnostics heralds new era With a number of industry firsts and innovative applications for early disease detection and monitoring, including a market leadership position in point of care coagulation management, Roche is now ... more Published on: 30 September 2011 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus ... more Published on: 29 September 2011 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. more Published on: 25 September 2011 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). more Published on: 23 September 2011 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and ... more Published on: 22 September 2011 Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment A team of researchers from Roche, including scientists from Roche Pharma Research and Early Development and Roche NimbleGen, reported in Genome Research that they have generated the first draft ... more Published on: 21 September 2011 First website focusing on early-stage Alzheimer's disease launches on World Alzheimer's Day Roche today announced the launch of a new website, www.earlysymptomsalzheimers.com, designed to provide healthcare professionals, patients and caregivers with information about early-stage ... more Published on: 19 September 2011 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 ... more Published on: 15 September 2011 Roche's xCELLigence System Monitors Beating Periodicity of Stem Cell Derived Cardiomyocytes in Preclinical Safety Assessment Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In a new ... more Published on: 8 September 2011 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones ... more Published on: 6 September 2011 Erasmus University Medical Centre in Rotterdam Adopts Automated Target Enrichment Solution from Roche NimbleGen and Caliper Life Sciences for 3,000 Sample Exome Study The Genetic Laboratory of the Department of Internal Medicine at Erasmus University Medical Centre in Rotterdam has adopted the combined automated target enrichment solution from Roche and Caliper ... more Published on: 6 September 2011 Roche and Evotec agree to develop compound that could slow the progression of Alzheimer's disease more Published on: 1 September 2011 Roche Launches Cedex Bio Bioprocess Analyzer for Reliable Metabolite Profiling and Substrate Analysis in Biotherapeutics Manufacturing A vast majority of biotherapeutics are manufactured in either bacterial or mammalian expression systems. Metabolite profiling and substrate analysis during the fermentation process is critical to ... more Published on: 1 September 2011 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved ... more Published on: 24 August 2011 The Roy J. Carver Center for Genomics (CCG) Achieves Certified Service Provider status for Roche NimbleGen microarrays In May 2011, The University of Iowa, Roy J. Carver Center for Genomics (CCG), entered into an agreement with Roche NimbleGen to provide microarray services through the Roche NimbleGen Certified ... more Published on: 18 August 2011 Medicinal Genomics Sequences the Cannabis Genome Using Roche's GS FLX+ System Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, ... more Published on: 18 August 2011 Roche and PerkinElmer Enter into New Agreement for Distribution of NimbleGen CGX Cytogenetics Array Workflow Roche and PerkinElmer today announced a new supply agreement for distribution of the NimbleGen CGX microarray workflow, for use in constitutional disease research. more Published on: 17 August 2011 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as ... more Published on: 11 August 2011 Researchers Decode Genome of Atlantic Cod Using 454 Sequencing Systems In a study published online this week in Nature, an international team of researchers report the first complete sequence of the Atlantic cod genome and an unexpected discovery of the unique immune ... more Published on: 4 August 2011 Roche's investigational treatment for asthma met its primary endpoint in a phase II study Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. ... more Published on: 3 August 2011 Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the ... more Published on: 28 July 2011 Roche's xCELLigence MP Instrument Used in the First Human Kinome Screen for Dynamic RNA Inhibitor Phenotypes during Cell Proliferation RNA interference studies are a powerful technology for high-throughput screening. However, endpoint analyses only provide a snapshot of the analyzed cellular phenotype, as it is not possible to ... more Published on: 27 July 2011 „Roche Continents“ at the Salzburg Festival celebrates its five-year anniversary Roche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 ... more Published on: 26 July 2011 cobas b 123 POC system - Blood gas analyzer from Roche awarded gold and “red” in medical design excellence Roche is honored with the Gold Medical Design Excellence Award and Red Dot Design Award for the cobas b 123 POC system. The award ceremonies were held in New York in June for the Medical Design ... more Published on: 25 July 2011 Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa Early testing helps reduce the impact of HIV on infants. Roche announced today that it has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for ... more Published on: 22 July 2011 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a ... more Published on: 21 July 2011 Roche's xCELLigence RTCA Cardio Instrument Used to Estimate the Risk of Drug-induced Proarrhythmia in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes Cardiotoxicity, which results when drugs adversely affect the heart, explains why roughly one third of new pharmaceuticals are withdrawn from the market and why many compounds fail in late-stage ... more Published on: 21 July 2011 Roche on track – full year earnings outlook increased Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance. more Published on: 20 July 2011 Roche's Cellavista System Performs Cell Analytics for a Novel Automated High Throughput Cell Culture Platform for Regenerative Medicine Regenerative medicine is dependent on advances in tissue engineering, biochemistry and applied bioengineering to develop and produce cells and cell-based products that regenerate or repair damaged ... more Published on: 19 July 2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. more Published on: 15 July 2011 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. more Published on: 14 July 2011 Roche Announces Thomas Schinecker as New President of 454 Life Sciences 454 Life Sciences, a center of excellence of Roche's business unit Applied Science, and developer of the innovative GS Junior and GS FLX+ Systems for high-throughput DNA sequencing, announced that ... more Published on: 12 July 2011 Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing Roche and Caliper Life Sciences, Inc. today announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture ... more Published on: 30 June 2011 Roche Applied Science Launches the Ultracompact LightCycler Nano System Worldwide With “Size: Reduced. Fun: Amplified.”, Roche Applied Science launched its new real-time PCR system on June 27th, 2011. The small, silent, sleek LightCycler Nano Instrument supports state-of-the-art ... more Published on: 30 June 2011 Roche’s Avastin receives broader EU label for women with metastatic breast cancer Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast ... more Published on: 30 June 2011 Roche provides update from FDA hearing on Avastin for metastatic breast cancer FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory ... more Published on: 29 June 2011 High throughput EHEC Pathogen Examination of Stool Samples using Roche´s MagNA Pure 96 and LightCycler Systems During the last weeks, there has been a significant increase in the number of cases of bloody diarrhea associated with hemolytic-uremic syndrome (HUS) caused by enterohaemorrhagic Escherichia coli ... more Published on: 28 June 2011 Roche Launches GS FLX+ System Offering High-Quality, Sanger-like Reads with the Power of Next-Generation Throughput 454 Life Sciences, a Roche Company (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long ... more Published on: 24 June 2011 Roche and Evotec to jointly develop biomarkers in oncology Roche and Evotec AG today announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development. more Published on: 23 June 2011 Roche sets up R&D Institute in France to foster collaborative translational research Roche announced today the launch of a new R&D Institute in France under the lead of the company's Pharma Research and Early Development (pRED) unit. more Published on: 21 June 2011 Roche Diagnostics supports European Union's DETECTIVE Project to reduce Animal Testing The xCELLigence RTCA System of Roche is being used in the European Union’s DETECTIVE ("Detection of endpoints and biomarkers for repeated dose toxicity using in vitro systems”) Project, a joint study ... more Published on: 21 June 2011 15 years of growth above the market The Roche Diagnostics Division is celebrating the 15th anniversary of its Elecsys® platform, the company’s key driver in immunochemistry. Elecsys continually sets new standards in immunodiagnostics ... more Published on: 20 June 2011 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. more Published on: 16 June 2011 Roche´s xCELLigence RTCA HT System: Fully-automated Measurement of Therapeutic Targets` Cellular Activity High throughput, real time impedance-based secondary screening of Ox1 GPCR hits. Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the ... more Published on: 16 June 2011 Roche Children's Walk 2011: Employees worldwide walk on the same day to raise awareness for vulnerable children in Malawi and around the world Every year since 2003 Roche employees raise awareness for children in need by walking to collect donations for day-care centres in Malawi and children’s charities in their own countries. more Published on: 15 June 2011 Deadly E. Coli Strain Sequenced with Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences' benchtop GS Junior sequencing system to generate the "most ... more Published on: 14 June 2011 Data Quality Meets Enjoyment: Roche´s New Small LightCycler System Presented at Real-Time PCR Symposium in Prague At the “Developments in Real-Time PCR” Symposium in Prague, June 13th – 17th, Roche officially presented the latest addition to the company’s real-time PCR portfolio of LightCycler instruments. The ... more Published on: 9 June 2011 Agreement with Roche gives UCLA Stem Cell and Cancer Researchers Early Access to Leading-edge Technologies for the Advancement of Medical Research An agreement between UCLA and Roche will provide stem cell and cancer researchers with leading-edge technologies that will drive research capabilities and further the understanding of complex disease. more Published on: 5 June 2011 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase ... more Published on: 4 June 2011 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin ... more Published on: 3 June 2011 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC ... more Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers ... more Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer more Published on: 30 May 2011 Roche Applied Science and TIB Molbiol offer Assay Solution for Rapid EHEC Identification With the recent outbreak in Europe of Enterohaemorrhagic Escherichia coli (EHEC), Roche Applied Science and TIB Molbiol are providing scientists with complementary technologies that can be used for ... more Published on: 27 May 2011 Roche signs exclusive agreement with IT-IS Life Sciences Ltd on the new LightCycler Nano Instrument for low-throughput qPCR market Roche Applied Science has signed a worldwide exclusive OEM agreement with IT-IS Life Sciences Ltd for the distribution of the new LightCycler Nano Instrument, which will complete the company's ... more Published on: 26 May 2011 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League ... more Published on: 24 May 2011 454 Sequencing Systems Aid in Discovery of Novel Canine Hepatitis C Virus In a study published online this week in the Proceedings of the National Academy of Sciences, researchers report the use of high-throughput sequencing technology to identify a novel hepatitis C virus ... more Published on: 19 May 2011 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer more Published on: 18 May 2011 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented more Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness ... more Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C more Published on: 16 May 2011 Roche Diagnostics launches Vitamin D total assay With the launch of the Vitamin D total assay for the Elecsys analyzers and cobas modular platforms on May 13 in Europe as well as other regions including the CE mark Roche validates its leading ... more Published on: 12 May 2011 AgenoLAB Broadens Service Offering for Drug Development with Roche's RTCA Cardio Instrument AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA ... more Published on: 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to ... more Published on: 10 May 2011 Electrical Impedance as a Novel Biomarker of Myotube Atrophy and Hypertrophy - Measured with Roche's xCELLigence System Tracking physiological changes in skeletal muscle thickness is a direct and unbiased approach in screening therapeutic compounds that prevent skeletal muscle atrophy or induce hypertrophy. In a ... more Published on: 26 April 2011 BaseClear BV Certified to Provide NimbleGen Sequence Capture Services in The Netherlands Roche NimbleGen, a Roche Company announced today that the Netherlands-based genomic service provider BaseClear BV has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. ... more Published on: 20 April 2011 Roche's RTCA HT Instrument Adapts Real-Time Cell Analysis to a High-Throughput Format The new xCELLigence RTCA HT Instrument from Roche rounds out the Diagnostics Applied Science's portfolio in real-time cell analysis with a high-throughput product. more Published on: 20 April 2011 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This ... more Published on: 19 April 2011 Ambry Genetics Adds Certification of Roche NimbleGen CGH, DNA Methylation, Gene Expression, and ChIP-chip to Service Portfolio Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen Comparative ... more Published on: 18 April 2011 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for ... more Published on: 15 April 2011 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients more Published on: 14 April 2011 Is lunar dust harmful to humans? Roche’s xCELLigence System used to investigate effects of lunar and Martian dust on mammalian skin. Exposure to lunar dust during the Apollo missions resulted in reports of ocular, respiratory and ... more Published on: 14 April 2011 Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss ... more Published on: 11 April 2011 Roche and Lonza enter into MycoTOOL Distribution Agreement for Rapid Mycoplasma Testing Solutions Roche and Lonza announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL mycoplasma PCR assays. MycoTOOL detection kits are now ... more Published on: 7 April 2011 MIT's Koch Institute to use Roche LightCycler 480 System to help advance cancer research System used for detection of genetic material will help scientists explore molecular basis of diseases. Roche announced today that the David H. Koch Institute for Integrative Cancer Research at MIT ... more Published on: 7 April 2011 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known as TDM4450g, compared ... more Published on: 6 April 2011 Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C Roche Diagnostics is cooperating with the Spanish Vall d’Hebron Institute of Research (VHIR), the Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD), and the software ... more Published on: 5 April 2011 Roche and NuGEN Technologies Develop Whole Transcriptome Profiling Solution for 454 Sequencing Systems Roche and NuGEN Technologies to co-promote NuGEN’s Ovation RNA-Seq System with the GS FLX and GS Junior Systems to enable whole transcriptome profiling with low abundance RNA samples. 454 Life ... more Published on: 31 March 2011 Roche Diagnostics Announces the Appointment of Robert Yates as New Head of Roche Applied Science Roche Diagnostics announced today that effective from April 1, Robert Yates has been appointed as new Head of Roche Applied Science. He succeeds Manfred Baier, who will be retiring from Roche at the ... more Published on: 31 March 2011 Roche's test for Cytomegalovirus is approved in Europe Roche announced today that its Cytomegalovirus (CMV) test is now commercially available in Europe. CMV viral load testing helps physicians manage immunocompromised patients at risk of CMV disease, ... more Published on: 30 March 2011 Roche Introduces Next-Generation HLA Typing Solution for 454 Sequencing Systems 454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci ... more Published on: 29 March 2011 ATLAS Biolabs achieves Roche NimbleGen Certification for solution-based SeqCap EZ enrichment Roche NimbleGen announces that ATLAS Biolabs GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for SeqCap EZ ... more Published on: 23 March 2011 A life sciences renaissance: 125th peer-reviewed publication enabled by xCELLigence System To date, more than 125 peer-reviewed studies using Roche's xCELLigence System have been published, spanning a diverse group of applications, including cell invasion and migration of cancer cells, ... more Published on: 21 March 2011 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal ... more Published on: 17 March 2011 Research Study Characterized Analytical Performance and Clinical Potential of Roche Flu Test The availability of suitable diagnostic tools for identifying infected individuals is crucial for precise treatment in infectious diseases. The appearance of a novel pandemic human strain of ... more Published on: 16 March 2011 Using Roche's CASY Cell Counter and Analyzer for proliferation and viability measurement in cancer studies In a recent study, Prokop et al. used the CASY Cell Counter and Analyzer from Roche Applied Science to identify the specific anticancer properties of a therapeutic substance in Burkitt-like lymphoma ... more Published on: 15 March 2011 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in ... more Published on: 7 March 2011 Roche and RainDance Technologies Join Forces in Targeted Sequencing to Advance ADME Research RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, today announced collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution ... more Published on: 2 March 2011 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. more Published on: 1 March 2011 Roche Annual General Meeting: dividend raised by 10% Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total ... more Published on: 8 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until ... more Published on: 4 February 2011 First Duplex Test for Parvovirus B19 and Hepatitis A Virus Now Available in the US Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A ... more Published on: 2 February 2011 Solid overall results Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities more Published on: 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to ... more Published on: 28 January 2011 Early successful readout of Tarceva study in a distinct form of lung cancer Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim ... more Published on: 19 January 2011 Roche personalized investigational medicine shows survival benefit in advanced skin cancer Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 ... more Published on: 17 January 2011 454 Life Sciences, University of Florida, and DOE JGI Sequence Sweet Orange Genome, Publish Annotated Assembly to Public Database Researchers from the International Citrus Genomics Consortium announced this weekend at the Plant and Animal Genome (PAG) XIX conference in San Diego, California the availability of the sequence ... more Published on: 17 January 2011 Changes to the Roche Corporate Executive Committee Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans ... more Published on: 5 January 2011 FDA grants supplemental approval for ACTEMRA Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical ... more
Published on: 23 December 2011 Roche medicine Avastin receives EU approval for the treatment of women with newly diagnosed, advanced ovarian cancer Avastin represents first major treatment advance for women with ovarian cancer in 15 years. Roche announced today that the European Commission has approved Avastin (bevacizumab) in combination with ... more
Published on: 16 December 2011 Roche's personalized medicine Zelboraf receives positive opinion from European authority for the treatment of people with BRAF mutation-positive metastatic melanoma Roche, today announced that the Committee for Medicinal Products for Human Use (CHMP) has recommended that Zelboraf be granted full marketing authorization as a monotherapy for the treatment of adult ... more
Published on: 15 December 2011 Changes to the Roche Corporate Executive Committee Roche today announced that Sophie Kornowski-Bonnet, currently General Manager of Roche Pharma in France, has been appointed Head of Roche Partnering. Sophie Kornowski-Bonnet will assume her new role ... more
Published on: 8 December 2011 Roche announces positive results of pivotal Phase III study with pertuzumab in HER2-positive metastatic breast cancer Roche today announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab. The study compared the combination of pertuzumab, ... more
Published on: 7 December 2011 Roche establishes external Academic Translational Centre in Zurich Roche, together with ETH Zurich (Swiss Federal Institute of Technology, Zurich), the University of Zurich (UZH) and the University Hospital Zurich (USZ) announced today the formation of an external ... more
Published on: 7 December 2011 Roche establishes external Academic Translational Centre in Zurich more
Published on: 2 December 2011 Roche acquires Verum Diagnostica GmbH to strengthen portfolio in coagulation diagnostics Roche announced today that it has signed an agreement under which it will acquire 100 percent of Verum Diagnostica GmbH, based in Munich, Germany. Verum Diagnostica is a leading company in ... more
Published on: 1 December 2011 Roche's cobas EGFR Mutation Test For Personalized Treatment Of Non-Small Cell Lung Cancer Receives CE Mark New Test allows identification of lung cancer patients who may benefit from early treatment with EGFR inhibitors. Roche announced today that the cobas EGFR Mutation Test is now CE marked for ... more
Published on: 30 November 2011 Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium Roche today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer ... more
Published on: 29 November 2011 Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA) Collaboration offers new hope for a potential treatment for the leading genetic cause of death in infants and toddlers more
Published on: 29 November 2011 Roche signs agreement with PTC Therapeutics to advance treatment for Spinal Muscular Atrophy (SMA) more
Published on: 28 November 2011 Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research Roche NimbleGen, Inc. and BGI, the world’s largest genomic organization, announced that they have developed a Major Histocompatibility Complex (MHC) region capture technology based on NimbleGen ... more
Published on: 18 November 2011 FDA Commissioner Announces Final Decision on Avastin for Metastatic Breast Cancer U.S. Food and Drug Administration (FDA) Commissioner revokes approval of Avastin for treatment of metastatic breast cancer (mBC) in the United States. This action concludes the FDA’s review of ... more
Published on: 9 November 2011 FDA accepts Roche's New Drug Application for vismodegib in advanced form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted and filed the company’s New Drug Application for vismodegib for the treatment of adults with advanced basal cell ... more
Published on: 8 November 2011 Roche announces commercial availability of the new Elecsys PTH (1–84) assay Fully automated assay provides accurate assessment of parathyroid function in patients with chronic kidney disease in routine clinical practice. Roche announces the market availability of the Elecsys ... more
Published on: 3 November 2011 New study correlates sFlt-1/PIGF with disease severity in PE/HELLP Patients with a high sFlt-1/PIGF ratio show significantly increased risk for imminent delivery A new study now published in the American Journal of Obstetrics and Gynecology1 shows the ratio of angiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PIGF). ... more
Published on: 3 November 2011 NT-proBNP–guided therapy reduces cardiovascular event rates and improved quality of life in heart failure patients Positive study results promote a new paradigm in the management of heart failure. In the recently published PROTECT (Pro-BNP Outpatient Tailored Chronic HF Therapy) trial, a strategy of NT-proBNP ... more
Published on: 20 October 2011 Phase II study showed ocrelizumab maintained significant reduction in disease activity for multiple sclerosis patients for almost two years Phase III trials underway to investigate ocrelizumab in two forms of MS. Roche today announced 96-week results from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple ... more
Published on: 18 October 2011 Roche reports positive study of Herceptin given by subcutaneous injection Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin. Roche today announced that the Phase III HannaH study demonstrated comparable efficacy of a ... more
Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals Roche and Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS) today announced that the two companies have entered into a definitive merger agreement for Roche to fully acquire Anadys at a price of USD 3.70 ... more
Published on: 17 October 2011 Roche signs definitive agreement to acquire Anadys Pharmaceuticals more
Published on: 13 October 2011 Roche posts solid sales performance in first nine months, achieves significant progress with personalised healthcare approaches Group sales rise 2% at CER (-12% in Swiss francs; +7% in US dollars), excluding Tamiflu; Significant foreign exchange impact of -13% due to appreciation of Swiss franc; overall Group sales at 31.5 ... more
Published on: 11 October 2011 Roche Licenses Nanopore Sequencing Technologies from Arizona State University and Columbia University for Rapid, Affordable DNA Sequencing Roche and Arizona Technology Enterprises announced today an agreement to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. ... more
Published on: 10 October 2011 Study shows that Roche's investigational drug for Alzheimer's disease removes amyloid plaques from the brain Roche today announced the publication of a study demonstrating that its monoclonal antibody gantenerumab removes amyloid plaques from the brain of patients with Alzheimer’s disease. The study ... more
Published on: 10 October 2011 Roche NimbleGen Announces New Pre-capture Multiplexing for Target Enrichment Technology in Sequencing With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing. To enable researchers to ... more
Published on: 4 October 2011 Roche Redefines Global Coagulation Diagnostics The market leader of in vitro diagnostics heralds new era With a number of industry firsts and innovative applications for early disease detection and monitoring, including a market leadership position in point of care coagulation management, Roche is now ... more
Published on: 30 September 2011 Roche wins first major public tender in Europe to screen women for cervical cancer with its Human Papillomavirus test Roche announced today that it has been awarded an exclusive contract by Karolinska University Hospital in Stockholm, Sweden, to provide a diagnostic tool for primary screening of Human Papillomavirus ... more
Published on: 29 September 2011 Roche receives clearance from the U.S. Food and Drug Administration for new generation of Accu-Chek Aviva Plus Test Strips for people with diabetes Roche announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for its Accu-Chek Aviva Plus test system. more
Published on: 25 September 2011 Roche's investigational medicine T-DM1 shows improvement in progression-free survival compared to standard of care in HER2-positive metastatic breast cancer Roche today announced the results of the Phase II study TDM4450g in patients with previously untreated HER2-positive metastatic breast cancer (mBC). more
Published on: 23 September 2011 Roche's Avastin receives positive opinion from European authority for the treatment of women with newly diagnosed advanced ovarian cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the use of Avastin in combination with standard chemotherapy (carboplatin and ... more
Published on: 22 September 2011 Roche Researchers Sequence Complete Genome of Cynomolgus Monkey and Develop Novel Gene Expression Microarray for Drug Safety Assessment A team of researchers from Roche, including scientists from Roche Pharma Research and Early Development and Roche NimbleGen, reported in Genome Research that they have generated the first draft ... more
Published on: 21 September 2011 First website focusing on early-stage Alzheimer's disease launches on World Alzheimer's Day Roche today announced the launch of a new website, www.earlysymptomsalzheimers.com, designed to provide healthcare professionals, patients and caregivers with information about early-stage ... more
Published on: 19 September 2011 Roche highlights data that demonstrate a range of new approaches to target breast, skin and lung cancers at 2011 European Multidisciplinary Cancer Congress Roche today announced that encouraging data on its investigational and approved medicines will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm being held 23-27 ... more
Published on: 15 September 2011 Roche's xCELLigence System Monitors Beating Periodicity of Stem Cell Derived Cardiomyocytes in Preclinical Safety Assessment Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In a new ... more
Published on: 8 September 2011 Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year Reinforces commitment to creating long-term value for all stakeholders. Roche announced today that it has been recognized as the most sustainable healthcare company globally in the Dow Jones ... more
Published on: 6 September 2011 Erasmus University Medical Centre in Rotterdam Adopts Automated Target Enrichment Solution from Roche NimbleGen and Caliper Life Sciences for 3,000 Sample Exome Study The Genetic Laboratory of the Department of Internal Medicine at Erasmus University Medical Centre in Rotterdam has adopted the combined automated target enrichment solution from Roche and Caliper ... more
Published on: 6 September 2011 Roche and Evotec agree to develop compound that could slow the progression of Alzheimer's disease more
Published on: 1 September 2011 Roche Launches Cedex Bio Bioprocess Analyzer for Reliable Metabolite Profiling and Substrate Analysis in Biotherapeutics Manufacturing A vast majority of biotherapeutics are manufactured in either bacterial or mammalian expression systems. Metabolite profiling and substrate analysis during the fermentation process is critical to ... more
Published on: 1 September 2011 Roche's Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer Personalized approach to cancer medicine allows doctors to identify lung cancer patients who benefit from early treatment with Tarceva. Roche announced today that the European Commission has approved ... more
Published on: 24 August 2011 The Roy J. Carver Center for Genomics (CCG) Achieves Certified Service Provider status for Roche NimbleGen microarrays In May 2011, The University of Iowa, Roy J. Carver Center for Genomics (CCG), entered into an agreement with Roche NimbleGen to provide microarray services through the Roche NimbleGen Certified ... more
Published on: 18 August 2011 Medicinal Genomics Sequences the Cannabis Genome Using Roche's GS FLX+ System Medicinal Genomics, a private company headquartered in Marblehead, Mass., USA and the Netherlands, announced today that it has sequenced the entire genomes of Cannabis sativa and Cannabis indica, ... more
Published on: 18 August 2011 Roche and PerkinElmer Enter into New Agreement for Distribution of NimbleGen CGX Cytogenetics Array Workflow Roche and PerkinElmer today announced a new supply agreement for distribution of the NimbleGen CGX microarray workflow, for use in constitutional disease research. more
Published on: 17 August 2011 FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer Roche today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as ... more
Published on: 11 August 2011 Researchers Decode Genome of Atlantic Cod Using 454 Sequencing Systems In a study published online this week in Nature, an international team of researchers report the first complete sequence of the Atlantic cod genome and an unexpected discovery of the unique immune ... more
Published on: 4 August 2011 Roche's investigational treatment for asthma met its primary endpoint in a phase II study Roche today announced that a phase II study of its investigational treatment lebrikizumab, a humanized monoclonal antibody designed to block interleukin-13 (IL-13) cytokine, met its primary endpoint. ... more
Published on: 3 August 2011 Roche's RoACTEMRA approved in Europe for children living with a rare and severe form of arthritis Medicine offers new treatment option for Systemic Juvenile Idiopathic Arthritis (sJIA). Roche announced today that the European Commission has approved the use of RoACTEMRA (tocilizumab) for the ... more
Published on: 28 July 2011 Roche's xCELLigence MP Instrument Used in the First Human Kinome Screen for Dynamic RNA Inhibitor Phenotypes during Cell Proliferation RNA interference studies are a powerful technology for high-throughput screening. However, endpoint analyses only provide a snapshot of the analyzed cellular phenotype, as it is not possible to ... more
Published on: 27 July 2011 „Roche Continents“ at the Salzburg Festival celebrates its five-year anniversary Roche and the Salzburg Festival are celebrating the fifth- anniversary of their collaboration this year. Once again, as in the past years of cooperation, students of the sciences, art and music of 34 ... more
Published on: 26 July 2011 cobas b 123 POC system - Blood gas analyzer from Roche awarded gold and “red” in medical design excellence Roche is honored with the Gold Medical Design Excellence Award and Red Dot Design Award for the cobas b 123 POC system. The award ceremonies were held in New York in June for the Medical Design ... more
Published on: 25 July 2011 Roche to provide HIV/AIDS tests for Early Infant Diagnosis in South Africa Early testing helps reduce the impact of HIV on infants. Roche announced today that it has been awarded an exclusive contract by the National Health Laboratory Services (NHLS) in South Africa for ... more
Published on: 22 July 2011 Roche's Tarceva gains positive CHMP opinion for first-line use in genetically distinct type of lung cancer Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion in the EU supporting earlier, frontline use of Tarceva (erlotinib) in people with a ... more
Published on: 21 July 2011 Roche's xCELLigence RTCA Cardio Instrument Used to Estimate the Risk of Drug-induced Proarrhythmia in Human Induced Pluripotent Stem Cell Derived Cardiomyocytes Cardiotoxicity, which results when drugs adversely affect the heart, explains why roughly one third of new pharmaceuticals are withdrawn from the market and why many compounds fail in late-stage ... more
Published on: 21 July 2011 Roche on track – full year earnings outlook increased Group sales stable in local currencies. Excluding Tamiflu, Group sales up 2% and Pharmaceuticals Division sales up 1%; Diagnostics Division sales up 5%; on track to meet full-year guidance. more
Published on: 20 July 2011 Roche's Cellavista System Performs Cell Analytics for a Novel Automated High Throughput Cell Culture Platform for Regenerative Medicine Regenerative medicine is dependent on advances in tissue engineering, biochemistry and applied bioengineering to develop and produce cells and cell-based products that regenerate or repair damaged ... more
Published on: 19 July 2011 Roche acquires mtm laboratories AG, expanding offering in cervical cancer testing Roche announced today that it has signed an agreement under which it will acquire 100 percent of mtm laboratories AG (mtm), a privately-held company based in Heidelberg, Germany. more
Published on: 15 July 2011 Pertuzumab combined with Herceptin and chemotherapy significantly extended the time people with HER2-positive metastatic breast cancer lived without their disease getting worse Roche today announced that CLEOPATRA, a pivotal Phase III study, met its primary endpoint. more
Published on: 14 July 2011 Roche Announces Thomas Schinecker as New President of 454 Life Sciences 454 Life Sciences, a center of excellence of Roche's business unit Applied Science, and developer of the innovative GS Junior and GS FLX+ Systems for high-throughput DNA sequencing, announced that ... more
Published on: 12 July 2011 Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing Roche and Caliper Life Sciences, Inc. today announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture ... more
Published on: 30 June 2011 Roche Applied Science Launches the Ultracompact LightCycler Nano System Worldwide With “Size: Reduced. Fun: Amplified.”, Roche Applied Science launched its new real-time PCR system on June 27th, 2011. The small, silent, sleek LightCycler Nano Instrument supports state-of-the-art ... more
Published on: 30 June 2011 Roche’s Avastin receives broader EU label for women with metastatic breast cancer Expanded label allows combination with Xeloda or paclitaxel in first-line setting. Roche announced today that the European Commission has extended the existing Avastin (bevacizumab) metastatic breast ... more
Published on: 30 June 2011 Roche provides update from FDA hearing on Avastin for metastatic breast cancer FDA Commissioner to Make Final Decision at a Later Date. Roche announced today that, during a U.S. Food and Drug Administration (FDA) hearing on Wednesday, the FDA’s Oncologic Drugs Advisory ... more
Published on: 29 June 2011 High throughput EHEC Pathogen Examination of Stool Samples using Roche´s MagNA Pure 96 and LightCycler Systems During the last weeks, there has been a significant increase in the number of cases of bloody diarrhea associated with hemolytic-uremic syndrome (HUS) caused by enterohaemorrhagic Escherichia coli ... more
Published on: 28 June 2011 Roche Launches GS FLX+ System Offering High-Quality, Sanger-like Reads with the Power of Next-Generation Throughput 454 Life Sciences, a Roche Company (SIX: RO, ROG; OTCQX: RHHBY), announced today the launch and immediate availability of the new GS FLX+ System, an instrument capable of generating extra-long ... more
Published on: 24 June 2011 Roche and Evotec to jointly develop biomarkers in oncology Roche and Evotec AG today announced a collaboration in novel protein-activity based biomarkers for Roche’s oncology drugs under development. more
Published on: 23 June 2011 Roche sets up R&D Institute in France to foster collaborative translational research Roche announced today the launch of a new R&D Institute in France under the lead of the company's Pharma Research and Early Development (pRED) unit. more
Published on: 21 June 2011 Roche Diagnostics supports European Union's DETECTIVE Project to reduce Animal Testing The xCELLigence RTCA System of Roche is being used in the European Union’s DETECTIVE ("Detection of endpoints and biomarkers for repeated dose toxicity using in vitro systems”) Project, a joint study ... more
Published on: 21 June 2011 15 years of growth above the market The Roche Diagnostics Division is celebrating the 15th anniversary of its Elecsys® platform, the company’s key driver in immunochemistry. Elecsys continually sets new standards in immunodiagnostics ... more
Published on: 20 June 2011 Pivotal study showed vismodegib helped shrink tumours or heal lesions in people with rare form of advanced skin cancer Roche announced today that a pivotal Phase II study with vismodegib showed positive results in people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. more
Published on: 16 June 2011 Roche´s xCELLigence RTCA HT System: Fully-automated Measurement of Therapeutic Targets` Cellular Activity High throughput, real time impedance-based secondary screening of Ox1 GPCR hits. Label-free technologies have entered the stage of cellular drug discovery and high-throughput screening (HTS). For the ... more
Published on: 16 June 2011 Roche Children's Walk 2011: Employees worldwide walk on the same day to raise awareness for vulnerable children in Malawi and around the world Every year since 2003 Roche employees raise awareness for children in need by walking to collect donations for day-care centres in Malawi and children’s charities in their own countries. more
Published on: 15 June 2011 Deadly E. Coli Strain Sequenced with Roche GS Junior System by HPA Scientists - Provides Community Most Complete Assembly to Date The deadly E. coli O104 strain that has killed dozens and hospitalized thousands across Europe has been sequenced using 454 Life Sciences' benchtop GS Junior sequencing system to generate the "most ... more
Published on: 14 June 2011 Data Quality Meets Enjoyment: Roche´s New Small LightCycler System Presented at Real-Time PCR Symposium in Prague At the “Developments in Real-Time PCR” Symposium in Prague, June 13th – 17th, Roche officially presented the latest addition to the company’s real-time PCR portfolio of LightCycler instruments. The ... more
Published on: 9 June 2011 Agreement with Roche gives UCLA Stem Cell and Cancer Researchers Early Access to Leading-edge Technologies for the Advancement of Medical Research An agreement between UCLA and Roche will provide stem cell and cancer researchers with leading-edge technologies that will drive research capabilities and further the understanding of complex disease. more
Published on: 5 June 2011 Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations Roche’s Personalised Healthcare approach demonstrated through vemurafenib and its investigational companion diagnostic, Roche’s cobas 4800 BRAF V600 Mutation Test. Roche today announced that a Phase ... more
Published on: 4 June 2011 Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer Phase III OCEANS results add to the growing body of evidence supporting Avastin’s potential role in ovarian cancer. Roche today announced results from OCEANS, a phase III study evaluating Avastin ... more
Published on: 3 June 2011 Tarceva nearly doubled the time people with a genetically distinct type of lung cancer lived without their disease getting worse Roche today announced results of EURTAC, the first Phase III study with Tarceva (erlotinib) in Western patients with a genetically distinct type of advanced non-small cell lung cancer (NSCLC). EURTAC ... more
Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer Roche today announced that it has entered into a clinical collaboration agreement with Bristol-Myers Squibb Company (NYSE:BMY) to investigate the combination of vemurafenib with Bristol-Myers ... more
Published on: 2 June 2011 Roche enters collaboration with Bristol-Myers Squibb to study combination therapy with vemurafenib and ipilimumab in advanced skin cancer more
Published on: 30 May 2011 Roche Applied Science and TIB Molbiol offer Assay Solution for Rapid EHEC Identification With the recent outbreak in Europe of Enterohaemorrhagic Escherichia coli (EHEC), Roche Applied Science and TIB Molbiol are providing scientists with complementary technologies that can be used for ... more
Published on: 27 May 2011 Roche signs exclusive agreement with IT-IS Life Sciences Ltd on the new LightCycler Nano Instrument for low-throughput qPCR market Roche Applied Science has signed a worldwide exclusive OEM agreement with IT-IS Life Sciences Ltd for the distribution of the new LightCycler Nano Instrument, which will complete the company's ... more
Published on: 26 May 2011 RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis New study confirms RoACTEMRA is effective when used on its own for people who do not respond to methotrexate. Roche today announced new data from the ACT-RAY study, presented at the European League ... more
Published on: 24 May 2011 454 Sequencing Systems Aid in Discovery of Novel Canine Hepatitis C Virus In a study published online this week in the Proceedings of the National Academy of Sciences, researchers report the use of high-throughput sequencing technology to identify a novel hepatitis C virus ... more
Published on: 19 May 2011 MetMAb in combination with Tarceva doubled the time people with lung cancer lived without their disease getting worse Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer more
Published on: 18 May 2011 Roche to present significant progress in advanced skin, lung and ovarian cancers at ASCO Progress in advanced skin and lung cancers through personalised healthcare. New Phase III data for Avastin in ovarian cancer to be presented more
Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C Roche announced today that it has entered into agreements with Merck, known as MSD outside the United States, through their respective subsidiaries, to improve the treatment, diagnosis and awareness ... more
Published on: 17 May 2011 Roche and Merck Establish Strategic Agreements in Fight Against Chronic Hepatitis C more
Published on: 16 May 2011 Roche Diagnostics launches Vitamin D total assay With the launch of the Vitamin D total assay for the Elecsys analyzers and cobas modular platforms on May 13 in Europe as well as other regions including the CE mark Roche validates its leading ... more
Published on: 12 May 2011 AgenoLAB Broadens Service Offering for Drug Development with Roche's RTCA Cardio Instrument AgenoLAB, the Stuttgart-based service provider, is the first company in Germany to expand its service offering with the latest cell analysis technology from Roche. The company will use the RTCA ... more
Published on: 11 May 2011 New drug applications submitted in the United States and Europe for vemurafenib in advanced skin cancer Roche today announced that the company submitted a New Drug Application for vemurafenib (RG7204, PLX4032) to the U.S. Food and Drug Administration (FDA) and a Marketing Authorization Application to ... more
Published on: 10 May 2011 Electrical Impedance as a Novel Biomarker of Myotube Atrophy and Hypertrophy - Measured with Roche's xCELLigence System Tracking physiological changes in skeletal muscle thickness is a direct and unbiased approach in screening therapeutic compounds that prevent skeletal muscle atrophy or induce hypertrophy. In a ... more
Published on: 26 April 2011 BaseClear BV Certified to Provide NimbleGen Sequence Capture Services in The Netherlands Roche NimbleGen, a Roche Company announced today that the Netherlands-based genomic service provider BaseClear BV has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. ... more
Published on: 20 April 2011 Roche's RTCA HT Instrument Adapts Real-Time Cell Analysis to a High-Throughput Format The new xCELLigence RTCA HT Instrument from Roche rounds out the Diagnostics Applied Science's portfolio in real-time cell analysis with a high-throughput product. more
Published on: 20 April 2011 FDA Approves Roche's HPV Test for Identifying Women at Highest Risk for Cervical Cancer Roche announced today that the US Food and Drug Administration (FDA) has approved the cobas HPV (Human Papillomavirus) Test which identifies women at highest risk for developing cervical cancer. This ... more
Published on: 19 April 2011 Ambry Genetics Adds Certification of Roche NimbleGen CGH, DNA Methylation, Gene Expression, and ChIP-chip to Service Portfolio Roche NimbleGen announces that Southern California (Aliso Viejo) based genomic services provider Ambry Genetics has officially become a Certified Service Provider (CSP) for NimbleGen Comparative ... more
Published on: 18 April 2011 FDA approves Actemra for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) Medicine offers a new option for children living with a rare and severe form of arthritis. Roche today announced that the United States (U.S.) Food and Drug Administration (FDA) approved Actemra for ... more
Published on: 15 April 2011 Roche gains positive CHMP opinion for the combination of Avastin with Xeloda as a first-line treatment for metastatic breast cancer in Europe Approval would allow combination of Avastin with paclitaxel or Xeloda, offering more choice to physicians and patients more
Published on: 14 April 2011 Is lunar dust harmful to humans? Roche’s xCELLigence System used to investigate effects of lunar and Martian dust on mammalian skin. Exposure to lunar dust during the Apollo missions resulted in reports of ocular, respiratory and ... more
Published on: 14 April 2011 Roche Group’s first-quarter 2011 sales on track for full-year targets – positive results in seven key clinical trials Group sales stable in local currencies (-9% in Swiss francs; +2% in US dollars) at 11.1 billion Swiss francs in first three months of 2011. Excluding Tamiflu, Group sales rise 2% (-7% in Swiss ... more
Published on: 11 April 2011 Roche and Lonza enter into MycoTOOL Distribution Agreement for Rapid Mycoplasma Testing Solutions Roche and Lonza announced today that they have entered into a co-exclusive distribution agreement for the commercialization of Roche’s MycoTOOL mycoplasma PCR assays. MycoTOOL detection kits are now ... more
Published on: 7 April 2011 MIT's Koch Institute to use Roche LightCycler 480 System to help advance cancer research System used for detection of genetic material will help scientists explore molecular basis of diseases. Roche announced today that the David H. Koch Institute for Integrative Cancer Research at MIT ... more
Published on: 7 April 2011 Roche announces positive Phase II results for trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer Roche today announced topline results of its first randomized trial of trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer. The Phase II trial, known as TDM4450g, compared ... more
Published on: 6 April 2011 Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C Roche Diagnostics is cooperating with the Spanish Vall d’Hebron Institute of Research (VHIR), the Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBEREHD), and the software ... more
Published on: 5 April 2011 Roche and NuGEN Technologies Develop Whole Transcriptome Profiling Solution for 454 Sequencing Systems Roche and NuGEN Technologies to co-promote NuGEN’s Ovation RNA-Seq System with the GS FLX and GS Junior Systems to enable whole transcriptome profiling with low abundance RNA samples. 454 Life ... more
Published on: 31 March 2011 Roche Diagnostics Announces the Appointment of Robert Yates as New Head of Roche Applied Science Roche Diagnostics announced today that effective from April 1, Robert Yates has been appointed as new Head of Roche Applied Science. He succeeds Manfred Baier, who will be retiring from Roche at the ... more
Published on: 31 March 2011 Roche's test for Cytomegalovirus is approved in Europe Roche announced today that its Cytomegalovirus (CMV) test is now commercially available in Europe. CMV viral load testing helps physicians manage immunocompromised patients at risk of CMV disease, ... more
Published on: 30 March 2011 Roche Introduces Next-Generation HLA Typing Solution for 454 Sequencing Systems 454 Life Sciences, a Roche Company, announced today the launch and immediate availability of the new GS GType HLA Primer Sets for high- and medium-resolution genotyping of class I and class II loci ... more
Published on: 29 March 2011 ATLAS Biolabs achieves Roche NimbleGen Certification for solution-based SeqCap EZ enrichment Roche NimbleGen announces that ATLAS Biolabs GmbH, located in Berlin, Germany, has passed the certification process to qualify as a Roche NimbleGen Certified Service Provider (CSP) for SeqCap EZ ... more
Published on: 23 March 2011 A life sciences renaissance: 125th peer-reviewed publication enabled by xCELLigence System To date, more than 125 peer-reviewed studies using Roche's xCELLigence System have been published, spanning a diverse group of applications, including cell invasion and migration of cancer cells, ... more
Published on: 21 March 2011 Roche announces positive pivotal Phase II results for Hedgehog Pathway Inhibitor in advanced basal cell carcinoma Roche today announced that a pivotal Phase II clinical study of its investigational Hedgehog Pathway Inhibitor, vismodegib (RG3616/GDC-0449), showed positive results in people with advanced basal ... more
Published on: 17 March 2011 Research Study Characterized Analytical Performance and Clinical Potential of Roche Flu Test The availability of suitable diagnostic tools for identifying infected individuals is crucial for precise treatment in infectious diseases. The appearance of a novel pandemic human strain of ... more
Published on: 16 March 2011 Using Roche's CASY Cell Counter and Analyzer for proliferation and viability measurement in cancer studies In a recent study, Prokop et al. used the CASY Cell Counter and Analyzer from Roche Applied Science to identify the specific anticancer properties of a therapeutic substance in Burkitt-like lymphoma ... more
Published on: 15 March 2011 Roche acquires PVT to strengthen laboratory automation in clinical diagnostics Roche announced today the acquisition of PVT Probenverteiltechnik GmbH based in Waiblingen, Germany and of PVT Lab Systems, LLC based in Atlanta, Georgia, USA. PVT is a global market leader in ... more
Published on: 7 March 2011 Roche and RainDance Technologies Join Forces in Targeted Sequencing to Advance ADME Research RainDance Technologies, Inc., and 454 Life Sciences, a Roche Company, today announced collaboration for the development and commercialization of a targeted next-generation sequencing (NGS) solution ... more
Published on: 2 March 2011 European Commission continues to support Avastin in combination with paclitaxel as an effective treatment option for women with metastatic breast cancer Roche announced today that the European Commission confirmed that Avastin (bevacizumab) in combination with paclitaxel will remain a treatment option for women with metastatic breast cancer in Europe. more
Published on: 1 March 2011 Roche Annual General Meeting: dividend raised by 10% Roche's Annual General Meeting, which was held today in Basel, has approved all of the Board of Directors' proposals. The 818 shareholders in attendance, representing 142,963,212 or 89.4% of a total ... more
Published on: 8 February 2011 Third phase III study of Avastin-based regimen met primary endpoint in ovarian cancer Roche announced today that OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (carboplatin and gemcitabine) followed by continued use of Avastin alone until ... more
Published on: 4 February 2011 First Duplex Test for Parvovirus B19 and Hepatitis A Virus Now Available in the US Roche announced today that the cobas TaqScreen DPX Test for use on the cobas s 201 system is now available in the US. It is the first commercial test to quantify parvovirus B19 and detect hepatitis A ... more
Published on: 2 February 2011 Solid overall results Mid-single digit sales growth in local currencies excluding Tamiflu - Strong profit growth - Promising late stage pharmaceutical pipeline of twelve new molecular entities more
Published on: 31 January 2011 FDA approves Rituxan/MabThera for first-line maintenance use in follicular lymphoma Roche today announced that the U.S. Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) as a maintenance treatment for patients with advanced follicular lymphoma who responded to ... more
Published on: 28 January 2011 Early successful readout of Tarceva study in a distinct form of lung cancer Roche today announced that an independent data monitoring committee has recommended that the phase III EURTAC study be stopped early because the study met its primary endpoint. At a planned interim ... more
Published on: 19 January 2011 Roche personalized investigational medicine shows survival benefit in advanced skin cancer Roche today announced that BRIM3, a Phase III clinical study of RG7204 (PLX4032), met its co-primary endpoints showing a significant survival benefit in people with previously untreated BRAF V600 ... more
Published on: 17 January 2011 454 Life Sciences, University of Florida, and DOE JGI Sequence Sweet Orange Genome, Publish Annotated Assembly to Public Database Researchers from the International Citrus Genomics Consortium announced this weekend at the Plant and Animal Genome (PAG) XIX conference in San Diego, California the availability of the sequence ... more
Published on: 17 January 2011 Changes to the Roche Corporate Executive Committee Erich Hunziker (born 1953), Chief Financial Officer, Chief Information Officer and Deputy Head of the Corporate Executive Committee has decided to retire from Roche at the end of March 2011 and plans ... more
Published on: 5 January 2011 FDA grants supplemental approval for ACTEMRA Roche today announced that the United States Food and Drug Administration has extended the ACTEMRA label to include inhibition and slowing of structural joint damage, improvement of physical ... more